96 results
8-K/A
EX-99.7
KA
Kineta Inc
3 Feb 21
Other Events
4:59pm
U.S. federal and state net operating loss carryforwards of $84.7 million and $84.8 million, respectively, which may be available to offset future income … to offset future tax liabilities and each begin to expire in 2035 and 2031, respectively. Yumanity has recorded a full valuation allowance against its net
8-K/A
EX-99.2
KA
Kineta Inc
3 Feb 21
Other Events
4:59pm
million, respectively, which may be available to offset future income tax liabilities. As of December 31, 2019, $34.6 million of federal net operating loss … and $1.1 million, respectively, which may be available to offset future tax liabilities and each begin to expire in 2035 and 2031, respectively
8-K
EX-99.4
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
offset by KVA12123 as we ramped up our activities in anticipation of initiating Phase 1 clinical trials in the fourth quarter of 2022.
General … , partially offset by KVA12123 as we ramped up our activities in anticipation of initiating Phase 1 clinical trials in the fourth quarter of 2022. The decrease
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
space, partially offset by higher activities for KVA12123, our lead product candidate, and CD27 licensing expense.
General and administrative expense … , 2023. The decrease was primarily due to a decrease in personnel costs of $538,000 and other administrative expenses of $328,000, partially offset
DEFA14A
KA
Kineta Inc
22 Apr 21
Additional proxy soliciting materials
4:49pm
with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
8-K
EX-99.1
wph u9rskl
31 Mar 21
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
8:55am
DEFA14A
nl2kdypilgn619he0
30 Apr 19
Additional proxy soliciting materials
4:08pm
DEFA14A
ul820z5h
29 Apr 20
Additional proxy soliciting materials
4:23pm
DEFA14A
a3uluw uyyv
13 May 19
Additional proxy soliciting materials
8:02am
DEFA14A
4f9 ptwe7pxzfmp7fka1
5 Jun 20
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
l5o dcslf
8 May 19
Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
5:15pm
8-K
EX-99.1
7kd9ni8
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm